The existing medicine stocks in Romania are sufficient for approximately two months and national supply is running smoothly, the Employers' Association of Industrial Producers of Medicines in Romania (PRIMER) said, advising the public not to stockpile, as excessive purchases can create imbalances.
"In the context of the conflict in the Middle East, Romania's medicine stocks are sufficient for approximately two months under normal consumption conditions. Currently, PRIMER does not recommend individual stockpiling, as excessive purchases can disrupt the market and affect other patients' access to essential treatments," a PRIMER release sent to AGERPRES on Monday informed.
According to PRIMER, which gathers the country's 17 leading pharmaceutical factories, this recommendation comes in the context of geopolitical tensions in the Middle East, which are affecting trade routes and driving up the costs of raw materials and transport, including fuel and gas, used in medicine production.
The employers' association said it is closely monitoring developments in the region, particularly the impact of military operations on international trade routes, including potential disruptions to transit through the Strait of Hormuz. At the same time, local medicine producers continue their operations and closely track stocks and supply flows to ensure uninterrupted production.
"However, PRIMER warns that if the current situation continues or worsens, supply delays may occur. Shipments from Asia could take up to two weeks longer due to disruptions along the Bab-el-Mandeb Strait and the Suez Canal, and costs could rise, which would put pressure on supply chains," according to the quoted source.
Meanwhile, the Ministry of Health has set up a working group to assess risks and identify solutions, with its first meeting scheduled on Monday, 30 March.
"In this context, it is important to act responsibly and avoid excessive medicine purchases. Individual stockpiling is not necessary at this time. Such behaviour can create artificial market imbalances and affect other patients' access to the treatments they need," PRIMER Executive Director dr Dragos Damian said, as quoted in the release.
Comentează